These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 10662870)

  • 1. Economic burden of rheumatoid arthritis: a systematic review.
    Cooper NJ
    Rheumatology (Oxford); 2000 Jan; 39(1):28-33. PubMed ID: 10662870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
    Michaud K; Messer J; Choi HK; Wolfe F
    Arthritis Rheum; 2003 Oct; 48(10):2750-62. PubMed ID: 14558079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.
    Rosery H; Bergemann R; Maxion-Bergemann S
    Pharmacoeconomics; 2005; 23(3):243-57. PubMed ID: 15836006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study.
    Lajas C; Abasolo L; Bellajdel B; Hernández-García C; Carmona L; Vargas E; Lázaro P; Jover JA
    Arthritis Rheum; 2003 Feb; 49(1):64-70. PubMed ID: 12579595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
    Hu H; Luan L; Yang K; Li SC
    Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A multicenter cross-sectional study on the health related quality of life of patients with rheumatoid arthritis using a revised Japanese version of the arthritis impact measurement scales version 2 (AIMS 2), focusing on the medical care costs and their associative factors].
    Hashimoto A; Sato H; Nishibayahi Y; Shiino Y; Kutsuna T; Ishihara Y; Hoshi K; Fujimori J; Tsuboi S; Kondo H; Akizuki M; Moroi Y; Yoshida S
    Ryumachi; 2002 Feb; 42(1):23-39. PubMed ID: 11925904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists.
    Guillemin F; Durieux S; Daurès JP; Lafuma A; Saraux A; Sibilia J; Bourgeois P; Sany J
    J Rheumatol; 2004 Jul; 31(7):1297-304. PubMed ID: 15229947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the lifetime costs of rheumatoid arthritis.
    Gabriel SE; Crowson CS; Luthra HS; Wagner JL; O'Fallon WM
    J Rheumatol; 1999 Jun; 26(6):1269-74. PubMed ID: 10381041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.
    Mennini FS; Marcellusi A; Gitto L; Iannone F
    Clin Drug Investig; 2017 Apr; 37(4):375-386. PubMed ID: 28074337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
    Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
    Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.
    Kobelt G; Jönsson L; Lindgren P; Young A; Eberhardt K
    Arthritis Rheum; 2002 Sep; 46(9):2310-9. PubMed ID: 12355478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV; Chiou CF; Dubois RW
    J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand.
    Osiri M; Maetzel A; Tugwell P
    J Rheumatol; 2007 Jan; 34(1):57-63. PubMed ID: 17183621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-of-illness studies in systemic lupus erythematosus: A systematic review.
    Zhu TY; Tam LS; Li EK
    Arthritis Care Res (Hoboken); 2011 May; 63(5):751-60. PubMed ID: 21557530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.
    Hsieh PH; Wu O; Geue C; McIntosh E; McInnes IB; Siebert S
    Ann Rheum Dis; 2020 Jun; 79(6):771-777. PubMed ID: 32245893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Societal cost of rheumatoid arthritis patients in the US.
    Birnbaum H; Pike C; Kaufman R; Marynchenko M; Kidolezi Y; Cifaldi M
    Curr Med Res Opin; 2010 Jan; 26(1):77-90. PubMed ID: 19908947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis.
    Hresko A; Lin TC; Solomon DH
    Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1431-1438. PubMed ID: 29316377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The excess burden of rheumatoid arthritis in Ontario, Canada.
    Tarride JE; Haq M; Nakhai-Pour HR; O'Reilly DJ; Xie F; Dolovich L; Blackhouse G; Goeree R
    Clin Exp Rheumatol; 2013; 31(1):18-24. PubMed ID: 23043846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project).
    Hallert E; Husberg M; Skogh T
    Rheumatology (Oxford); 2006 Mar; 45(3):325-31. PubMed ID: 16287927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.